Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term Safety of Z-338 in Functional Dyspepsia
NCT01973790Phase 3Completed
- Sponsor
- Zeria Pharmaceutical Co., Ltd.
- Start
- Mar 2014
- Primary completion
- Nov 2016
- Modality
- Small Molecules
- Countries
- 10
01
Overview
Phase 3, open-label, single-arm trial of acotiamide in functional dyspepsia (FD), sponsored by Zeria Pharmaceutical Co., Ltd. Primary endpoint: General safety endpoints up to 58 weeks. Started Mar 2014; status: completed.
02
Drugs
acotiamide
03
Conditions
functional dyspepsia (FD)
Beyond the preview
Go deeper on NCT01973790.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01973790.